CYP2C19 Genotype, Clopidogrel, and PCI Outcomes

CYP2C19 genotype, Clopidogrel, and PCI Outcomes
The platelet aggregation inhibitor clopidogrel requires biotransformation by cytochrome P450 (CYP)
Isoenzymes, and evidence suggests that reduced-function variants in the CYP2C19 may
associated with reduced platelet inhibition. Mega and colleagues analyzed patient level
Data from 9 trials, the CYP2C19 genotype and clinical results evaluated
Patients treated with clopidogrel (in primary percutaneous coronary intervention for
acute coronary syndrome) and found that even a reduced transport function CYP2C19
Allele with an increased risk of serious cardiovascular events associated-especially
Stent thrombosis. In an editorial discussing the clinical implications Fuster and Sweeny
the results of the study